U.S. FDA gives full approval of Eisai's new Alzheimer’s drug

According to The Jiji News, the U.S. Food and Drug Administration said it has given full approval of a new Alzheimer's drug jointly developed by Japanese drugmaker Eisai Co. and U.S. biopharmaceutical company Biogen Inc.
In January, the FDA approved the use of Leqembi, whose generic name is lecanemab, for the first time in the world under the accelerated approval procedures. As this approval was something like a provisional license, the drug was not widely covered by public health insurance.

https://sp.m.jiji.com/english/show/27204